Lv11
44 积分 2024-02-28 加入
Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis
2小时前
已完结
Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
2小时前
已完结
A platinated prodrug leveraging PROTAC technology for targeted protein degradation and enhanced antitumor efficacy
2小时前
已完结
Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation
1天前
已完结
Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6 Targeting Antibody Drug Conjugate
5天前
已完结
Degrader-antibody conjugates
22天前
已完结
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders
25天前
已完结
Discovery of SMD-3236: A Potent, Highly Selective and Efficacious SMARCA2 Degrader for the Treatment of SMARC4-Deficient Human Cancers
25天前
已完结
Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax , and Low Glucuronide Formation
1个月前
已完结
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
1个月前
已完结
How does equity restriction affect innovation quality? Evidence from listed manufacturing companies in China
皖公网安备34019202002308
